|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 177,600.00 KRW | +3.14% |
|
+1.02% | +3.03% |
| 01:29pm | Celltrion Submits EMA Marketing Authorization Application for Cosentyx Biosimilar CT-P55 | MT |
| 01:24pm | Celltrion Submits Dual-Part EMA Application for Subcutaneous Rheumatoid Arthritis Drug | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 26.77B | |||||
| 46.35B | |||||
| 40.13B | - | - | - | - | - |
| 36.33B | |||||
| 34.6B | |||||
| 16.66B | - |
- Stock Market
- Stocks
- A068270 Stock
- Charts Celltrion, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
